Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register

Explore journal

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 1040 Accesses	Review Resting state functional MRI in Alzheimer's Disease Prashanthi Vemuri, David T Jones, Clifford R Jack Alzheimer's Research & Therapy 2011, 4:2 (10 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Vemuri and colleagues discuss the use of resting-state functional magnetic resonance imaging (fMRI) as an emerging Alzheimer's disease biomarker and consider future developments and open questions in the field.
	2. 739 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed
	3. 661 Accesses	Review Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review Helena C Chui, Ling Zheng, Bruce R Reed, Harry V Vinters, Wendy J Mack Alzheimer's Research & Therapy 2011, 4:1 (4 January 2012) Abstract \| Full text \| PDF \| Editor’s summary Current studies fail to show a positive association between vascular risk factors and an increase in Alzheimer's disease (AD) pathology, as discussed in an evidence-based review by Chui and colleagues.
	4. 578 Accesses	Commentary Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design Benjamin Wolozin Alzheimer's Research & Therapy 2011, 4:3 (16 January 2012) Abstract \| Full text \| PDF
	5. 533 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	6. 468 Accesses	Research A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:29 (15 October 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A Quick Test of cognitive speed is twice as sensitive as the mini-mental state examination in evaluating cholinesterase inhibitor treatment in Alzheimer’s disease patients, indicating its potential usefulness in the primary care setting.
	7. 443 Accesses	Review Lipidomics of Alzheimer's disease: current status Paul L Wood Alzheimer's Research & Therapy 2012, 4:5 (1 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Current applications of lipidomic technologies and the potential roles of lipid deficits and alterations in the pathophysiology of Alzheimer's disease (AD) are discussed by Wood.
	8. 441 Accesses	Review Progranulin axis and recent developments in frontotemporal lobar degeneration Alexandra M Nicholson, Jennifer Gass, Leonard Petrucelli, Rosa Rademakers Alzheimer's Research & Therapy 2012, 4:4 (23 January 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Recent data involving progranulin protein (PGRN) biology and frontotemporal lobar degeneration (FTLD), and the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration, is discussed by Nicholson and colleagues.
	9. 420 Accesses	Review Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development Agneta Nordberg Alzheimer's Research & Therapy 2011, 3:34 (2 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Nordberg reviews recent progress in molecular imaging and functional biomarkers, which can provide valuable information for early Alzheimer's disease (AD) detection, assessing disease progression, and the development of new therapeutics.
	10. 416 Accesses	Commentary Predicting Alzheimer's risk: why and how? Deborah E Barnes, Sei J Lee Alzheimer's Research & Therapy 2011, 3:33 (25 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In light of recent research, Barnes and Lee consider the current limitations and future directions in identifying individuals at increased risk of developing symptomatic Alzheimer's disease (AD).
	11. 411 Accesses	Review Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications Robert Laforce, Gil D Rabinovici Alzheimer's Research & Therapy 2011, 3:31 (10 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Potential clinical applications of amyloid positron emission tomography (PET) and its role in the differential diagnosis of a range of neurodegenerative conditions are reviewed by Laforce and Rabinovici.
	12. 341 Accesses	Meeting report Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias Rachel F Lane, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:36 (20 December 2011) Abstract \| Full text \| PDF \| PubMed
	13. 300 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	14. 280 Accesses	Review Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease Lori Frank, William R Lenderking, Kellee Howard, Marc Cantillon Alzheimer's Research & Therapy 2011, 3:35 (9 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The uses of, and issues associated with, patient-reported outcome measures in mild cognitive impairment and prodromal Alzheimer's disease are discussed by Frank and colleagues.
	15. 271 Accesses	Review Genetics of Alzheimer disease in the pre- and post-GWAS era Nilüfer Ertekin-Taner Alzheimer's Research & Therapy 2010, 2:3 (5 March 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ertekin-Taner summarises genetic studies preceding the genome-wide association study (GWAS) era and discusses insights into genetics of Alzheimer’s following recent GWAS results, which may translate into future therapies.
	16. 252 Accesses	Research A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery Steven D Shirk, Meghan B Mitchell, Lynn W Shaughnessy, Janet C Sherman, Joseph J Locascio, Sandra Weintraub, Alireza Atri Alzheimer's Research & Therapy 2011, 3:32 (11 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Uniform Data Set clinical researchers are provided with a new online interactive calculator that provides a normative score to help evaluate neuropsychological test performance in subjects with Alzheimer's disease.
	17. 233 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	18. 233 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	19. 224 Accesses	Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
	20. 221 Accesses	Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
	21. 215 Accesses	Review Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney, Juha Yrjänheikki, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:28 (28 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Shineman and colleagues review the contribution of animal models to the understanding of biological mechanisms in Alzheimer's disease (AD) and how the translation of these models to human clinical trials might be improved.
	22. 208 Accesses	Review The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Kerensa Broersen, Frederic Rousseau, Joost Schymkowitz Alzheimer's Research & Therapy 2010, 2:12 (14 July 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Amyloid beta has been identified as neurotoxic in patients with Alzheimer’s disease (AD), but we must take into account its structural characteristics, as well as size, when exploring AD development.
	23. 207 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.
	24. 188 Accesses	Research Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter, A David Smith Alzheimer's Research & Therapy 2011, 3:5 (17 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Levels of cerebrospinal fluid (CSF) beta amyloid and tau show non-linear relationships with cognitive scores, with more work necessary to be able to predict Alzheimer’s disease and monitor its progression.
	25. 184 Accesses	Research Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice Bin Li, Maria E Gonzalez-Toledo, Chun-Shu Piao, Allen Gu, Roger E Kelley, Li-Ru Zhao Alzheimer's Research & Therapy 2011, 3:8 (15 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stem cell factor and granulocyte-colony stimulating factor limit beta-amyloid accumulation in a mouse model suggesting treatment with hematopoeitic growth factors may offer a new therapeutic approach for Alzheimer’s disease.